Introduction Prostate cancer (PCa) is the most commonly diagnosed solid tumor among men in the United States and Europe. Even without treatment, PCa-specific mortality rates at 5 and 10 years remain low. Improvements in optimizing screening, diagnosis, and treatment have…
Introduction The legal implications of prostate cancer screening flow from the formalization of expert opinion and scientific data into clinical practice guidelines (CPGs). These guidelines are a nexus between the daily clinical practice of prostate cancer care and the broader…
PSA testing: an ongoing dialogue Prostate-specific antigen (PSA)-based screening for early detection of prostate cancer was approved in two stages by the US Food and Drug Administration (FDA). In 1986, the blood test was approved mainly to monitor disease status…
Introduction Today, cancer of the prostate has become an everyday problem in most urological practices. In this chapter we will review the coding and billing of the various services provided by urologists for this clinical problem. The correct use of…
Erectile dysfunction (ED) is the most reported sexual dysfunction after prostate cancer treatments. However, there are other sexual dysfunctions that receive less attention and adversely impact quality of life after treatment, including absence of ejaculation, changes in orgasm or libido,…
Introduction Prostate cancer is the leading solid organ malignancy diagnosed in men in USA, with an estimated 238,590 cases in 2013. The diagnosis of prostate cancer brings about a significant change in the health-related quality of life (HRQOL) of the…
Introduction In contemporary clinical practice, multiple modalities of cancer treatment allow therapy to be tailored according to the continuum of disease severity. As trends in prostate cancer (PCa) presentation change, existing treatment options must be adapted to adjust risk and…
Introduction Increases in prostate cancer (PCa) screening due to the widespread use of prostate-specific antigen (PSA) has resulted in the diagnosis of more focal and clinically insignificant prostate adenocarcinomas. Active surveillance is often offered as an option for managing carefully…
Introduction According to data from the Surveillance, Epidemiology, and End Results (SEER) Program, 233,000 estimated new cases of prostate cancer (PCa) will have been diagnosed in the United States in 2014, and approximately 29,480 men will die of this disease.…
Introduction Androgen deprivation therapy (ADT) using the luteinizing hormone-releasing hormone (LHRH) agonist or antagonist has been the mainstay treatment of systemic hormone-sensitive prostate cancer. Following an initial decline in PSA levels and a clinically significant response rate of 80–90%, majority…